Clinical Trial

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, phase Ib/II study of YL202 in combination with other anti-tumor therapies to Evaluate the Safety, Tolerability, and Efficacy in Patients with Advanced Solid Tumors
Trial Details
NCT Number NCT07169994
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions Advanced Solid Tumors, Breast Cancer, Non Small Cell Lung Cancer
Enrollment 414 participants
Start Date 2025-09-02
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-12